Clincosm LogoSign in Get a demo

ImmuSMART: Immunization Services Model for Adult Rate Improvement

Sponsor
Pharmacy Quality Alliance (Other)
Overall Status
Completed
CT.gov ID
NCT02609035
Collaborator
(none)
22,301
Enrollment
2
Arms
12
Actual Duration (Months)

Study Details

Study Description

Brief Summary

ImmuSMART is a study of personalized telephonic prompts to community pharmacy patients to improve adult vaccination rates for pneumococcal and herpes zoster vaccines.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Telephonic prompt
 N/A

Detailed Description

This study will investigate immunization rate improvement among adult patients in 250 northeastern US community pharmacies as a result of telephonic prompts during regular automated outbound communiqués. There will be three projects assessing different forms of these appended prompts-appointment-based medication synchronization automated prompts, refill ready automated prompts, and refill reminder automated prompts. Each intervention will occur in one of three pharmacy chains, each with approximately 10,000 patients randomized to control or intervention (receive prompt or no).

Prior to the outbound automated call to the patient, a third-party technology vendor (Scientific Technologies Corporation) will perform an automated immunization status assessment of the patient by submitting a query the state immunization registry to compare the adult patient's existing immunization record to the CDC Recommended Adult Immunization Schedule. Gaps in immunizations that fall within pharmacy scope of practice will be identified. During the automated call (performed by VoicePort, a pharmacy telephonic support vendor) to the patient, they will be prompted to receive identified immunization gap vaccines upon their next pharmacy visit, with priority on pneumococcal, influenza, and herpes zoster vaccinations. If the patient accepts, the vaccination will be delivered when next the patient comes to visit the pharmacy.

After 6 months of running the trial, statistical modeling will be employed to assess vaccination rate differences between control and intervention patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
22301 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Health Services Research
Official Title:
Immunization Services Model for Adult Rate Improvement
Actual Study Start Date :
Mar 31, 2016
Actual Primary Completion Date :
Mar 31, 2017
Actual Study Completion Date :
Mar 31, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive a telephonic prompt to get a vaccination.

Behavioral: Telephonic prompt
Other Names:
  • Appended message

    		•
    No Intervention: Control

    Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive usual pharmacy care.

    Outcome Measures

    Primary Outcome Measures

    1. Vaccination rates [3 months]

      Administration of vaccine will be assessed at 3 months after patient receives the prompt

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patient at least 19 years of age at date of enrollment

    • Patient not in long-term care, hospice or otherwise identified as unable to come to pharmacy for receipt of vaccine

    • Patient currently missing a record of receipt of at least one of three vaccinations: flu, pneumonia, or shingles

    • Patient enrolled in telephonic pharmacy reminder service

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Pharmacy Quality Alliance

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Samuel Stolpe, Senior Director, Quality Strategies, Pharmacy Quality Alliance
    ClinicalTrials.gov Identifier:
    NCT02609035
    Other Study ID Numbers:
    • Pro00014163
    First Posted:
    Nov 20, 2015
    Last Update Posted:
    Apr 27, 2017
    Last Verified:
    Apr 1, 2017

    Study Results

    No Results Posted as of Apr 27, 2017